People · OnCo

A. Keith Stewart

Director, Princess Margaret Cancer Centre; Vice President, Cancer, University Health Network · Princess Margaret Cancer Centre

Keith Stewart is a myeloma researcher who leads Canada's largest cancer centre.

A. Murray Brunt

Professor of Clinical Oncology, Keele University; Consultant, University Hospitals of North Midlands

Led FAST-Forward, which cut breast radiotherapy from three weeks to one with no loss of effectiveness.

A. Oliver Sartor

Professor of Medical Oncology and Urology, Mayo Clinic · Mayo Clinic

Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.

Aaron Ciechanover

Distinguished Research Professor, Rappaport-Technion Integrated Cancer Center and Rappaport Faculty of Medicine, Technion · Technion, Israel Institute of Technology

Shared the 2004 Nobel Prize in Chemistry for discovering how cells label proteins for destruction. That labelling system is what proteasome inhibitors block and what every protein degrader hijacks.

Aaron D. Schimmer

Research Director, Princess Margaret Cancer Centre; Senior Scientist · Princess Margaret Cancer Centre

Leukaemia researcher who found that AML stem cells depend on mitochondrial proteases and metabolism.

Abhay Soi

Chairman and Managing Director, Max Healthcare Institute · Max Healthcare (Max Institute of Cancer Care)

Business leader who leads Max Healthcare, the Indian private hospital group whose network includes the Max Institute of Cancer Care.

Adda Bounedjar

Representative of Anti-Cancer Center of Blida to the Organisation of European Cancer Institutes · Anti-Cancer Center of Blida

Adda Bounedjar represents Anti-Cancer Center of Blida in the Organisation of European Cancer Institutes, which lists the organisation among its members in Algeria.

Aditya Bardia

Professor of Medicine and Director of Translational Research Integration, UCLA Jonsson Comprehensive Cancer Center · UCLA Jonsson Comprehensive Cancer Center

Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant.

Adrià Comella Carnicé

Representative of Hospital de la Santa Creu i Sant Pau to the Organisation of European Cancer Institutes · Hospital de la Santa Creu i Sant Pau

Adrià Comella Carnicé represents Hospital de la Santa Creu i Sant Pau in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.

Adrian Ochsenbein

Director UCI; Chief Physician, Medical Oncology · Inselspital, Bern University Hospital / University Cancer Center Inselspital

Bern medical oncology chief whose lab targets leukaemia stem cells and CD70 signalling.

Adrian R. Krainer

St. Giles Foundation Professor · Cold Spring Harbor Laboratory

Adrian Krainer invented the antisense drug nusinersen and studies how splicing errors drive cancer.

Aimery de Gramont

Head of Medical Oncology, Institut Hospitalier Franco-Britannique; Founder, GERCOR and ARCAD

Invented the FOLFOX regimen that anchors colorectal chemotherapy and founded the GERCOR and ARCAD trial groups.

Ajai Chari

Director of the Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center

Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma.

Akhil Kapoor

Medical oncologist, Homi Bhabha Cancer Hospital and MPMMCC, Varanasi (Tata Memorial Centre) · Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi

First author of METRO PLUS, the Varanasi trial that doubled survival in advanced head and neck cancer by adding cheap oral metronomic drugs to standard chemotherapy.

Akifumi Takaori

Director of Kyoto University Hospital · Kyoto University Hospital

Hematologist who directs Kyoto University Hospital, one of Japan's leading academic medical centres.

Alan Ashworth

President, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center

Co-discovered that BRCA-deficient cancers die when PARP is blocked, the idea behind an entire drug class.

Alan D. D'Andrea

Director, Susan F. Smith Center for Women's Cancers and Center for DNA Damage and Repair, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center

Mapped the Fanconi anaemia/BRCA DNA repair pathway and how tumours become resistant to PARP inhibitors.

Alan P. Venook

Shorenstein Associate Director for Program Development, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center

GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.

Alastair Greystoke

Professor of Precision Oncology, Newcastle University; Consultant Medical Oncologist, Northern Centre for Cancer Care; Clinical Director for Cancer, North East and Yorkshire Genomic Medicine Service · Newcastle Cancer Centre / Northern Centre for Cancer Care

The Newcastle oncologist who led the NHS England pilot that put a blood test for lung cancer mutations into the diagnostic pathway, and who co-leads the CONCORDE radiotherapy platform.

Albert C. Koong

Chair, Department of Radiation Oncology, MD Anderson · MD Anderson Cancer Center

Albert Koong is a radiation oncologist leading MD Anderson's radiation department, with a focus on pancreatic cancer and SBRT.

Albert Lasker

Advertising pioneer who co-founded the Lasker Foundation with Mary Lasker in 1942

The man who invented modern advertising put his fortune and his methods behind medical research, founding the Lasker Foundation with his wife Mary in 1942; after his death in 1952 she carried the campaign for cancer research into law.

Albert Salazar Soler

Representative of Vall d'Hebron University Hospital / VHIO to the Organisation of European Cancer Institutes · Vall d'Hebron University Hospital / VHIO

Albert Salazar Soler represents Vall d'Hebron University Hospital / VHIO in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.

Alberto Bardelli

Scientific Director, IFOM ETS - The AIRC Institute of Molecular Oncology; Professor, University of Turin · Istituto di Candiolo IRCCS (FPO)

Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade.

Alberto Gabizon

Oncologist, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School · Shaare Zedek Medical Center

The clinician half of the partnership that turned a liposome chemistry idea into Doxil, and the person who did the trials that showed it behaved differently in patients from free doxorubicin.

Aleix Prat

Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI · Hospital Clínic de Barcelona / IDIBAPS

Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy.

Aleksandar Sekulic

Dermatologist, Mayo Clinic Comprehensive Cancer Center in Arizona · Mayo Clinic Comprehensive Cancer Center in Arizona

Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.

Alessandro Delle Donne

Commissario Straordinario (Extraordinary Commissioner), IRCCS Istituto Tumori Giovanni Paolo II, Bari · IRCCS Istituto Tumori Giovanni Paolo II

Health manager who leads the IRCCS Istituto Tumori Giovanni Paolo II in Bari, first as Direttore Generale and, since 2025, as Commissario Straordinario.

Alessandro Gronchi

Chair, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori · Fondazione IRCCS Istituto Nazionale dei Tumori

Sarcoma surgeon who led the ISG-STS 1001 trial of histology-tailored neoadjuvant chemotherapy.

Alessandro Venturi

Representative of Fondazione IRCCS Policlinico San Matteo to the Organisation of European Cancer Institutes · Fondazione IRCCS Policlinico San Matteo

Alessandro Venturi represents Fondazione IRCCS Policlinico San Matteo in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.

Alex F. Herrera

Chief, Division of Lymphoma, City of Hope; SWOG Executive Officer, Leukemia/Lymphoma/Myeloma · City of Hope

Led the SWOG S1826 trial that made nivolumab part of first-line Hodgkin lymphoma treatment.

Alexander Drilon

Chief, Early Drug Development Service · Memorial Sloan Kettering Cancer Center

Led the trials of larotrectinib, entrectinib, repotrectinib and selpercatinib that turned rare gene fusions into treatable targets.

Alexander E. Perl

Professor of Medicine, Abramson Cancer Center, University of Pennsylvania · Abramson Cancer Center, University of Pennsylvania

Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML.

Alexander Eggermont

Chief Scientific Officer, Princess Máxima Center; Professor, Utrecht; former EORTC President · EORTC

Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.

Alexander J. Stratigos

Professor of Dermatology, National and Kapodistrian University of Athens, Andreas Sygros Hospital · National and Kapodistrian University of Athens, School of Medicine

Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines.

Alexandra "Alex" Scott

Child with neuroblastoma who started Alex's Lemonade Stand

Diagnosed with neuroblastoma before her first birthday, she set up a lemonade stand at four to raise money for her hospital. By her death at eight in 2004 it had raised $1 million; the foundation in her name has raised hundreds of millions since.

Alexandre Chan

President · Multinational Association of Supportive Care in Cancer

Oncology pharmacist-scientist at UC Irvine and President of MASCC, the multinational society for supportive care in cancer, known for research on cancer-related cognitive impairment.

Alexis Cortot

President · Intergroupe Francophone de Cancérologie Thoracique

Lille pulmonologist and thoracic oncologist who presides over the IFCT, France's academic lung cancer trials group.

Alfred P. Sloan Jr.

General Motors chairman who, with Charles Kettering, established the Sloan Kettering Institute

In the 1940s the General Motors chairman joined engineer Charles Kettering to establish the Sloan Kettering Institute, dedicated in 1948, which gave Memorial Hospital a research arm and its modern name.

Alfredo Addeo

Head of Division, Oncology · Geneva University Hospitals (HUG)

Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals.

Ali Taher

Director, Naef K. Basile Cancer Institute, American University of Beirut Medical Center · American University of Beirut Medical Center / Naef K. Basile Cancer Institute

Physician who directs the Naef K. Basile Cancer Institute, the multidisciplinary cancer centre of the American University of Beirut Medical Center in Lebanon.

Alice L. Yu

Professor of Pediatrics, UC San Diego; Children's Oncology Group immunotherapy investigator · Children's Oncology Group (COG)

Led the trial proving that an anti-GD2 antibody improves survival in high-risk neuroblastoma.

Alice P. Chen

Medical oncologist, Division of Cancer Treatment and Diagnosis, National Cancer Institute · National Cancer Institute (NIH)

NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer.

Alice T. Shaw

Thoracic oncologist and drug developer

Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs.

Alicia Jackson

Director of the Advanced Research Projects Agency for Health · Advanced Research Projects Agency for Health

Materials scientist and biotechnology founder who directs ARPA-H, the United States agency that funds high-risk, high-reward health research programmes.

Alinta Hegmane

Representative of Riga East University Hospital / Oncology Centre of Latvia to the Organisation of European Cancer Institutes · Riga East University Hospital / Oncology Centre of Latvia

Alinta Hegmane represents Riga East University Hospital / Oncology Centre of Latvia in the Organisation of European Cancer Institutes, which lists the centre among its members in Latvia.

Alon Chen

President · Weizmann Institute of Science

Neuroscientist who has been President of the Weizmann Institute of Science since 2019, leading one of the world's foremost basic research institutes, including its cancer research programmes.

Álvaro Bonet Pla

Representative of INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia to the Organisation of European Cancer Institutes · INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia

Álvaro Bonet Pla represents INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.

Amanda Nickles Fader

Gynaecologic oncologist, Johns Hopkins · Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center

Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer.

Amanda Pritchard

Chief Executive of Guy's and St Thomas' NHS Foundation Trust · Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre

Former head of NHS England who returned to lead Guy's and St Thomas' NHS Foundation Trust as Chief Executive in September 2025.

Amar Gajjar

Chair, Department of Pediatric Medicine, St. Jude Children's Research Hospital · St. Jude Children's Research Hospital

Led the St. Jude medulloblastoma trials that introduced molecular subgroups into risk-adapted treatment.

Amar U. Kishan

Professor and Vice Chair of Clinical and Translational Research, Radiation Oncology, UCLA · UCLA Jonsson Comprehensive Cancer Center

Radiation oncologist who showed MRI-guided prostate radiotherapy causes fewer side effects.

Amer M. Zeidan

Haematologist, Yale Cancer Center · Yale Cancer Center / Smilow Cancer Hospital

Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival.

Amit M. Oza

Head, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit · Princess Margaret Cancer Centre

Amit Oza is a gynaecologic oncologist who led early olaparib and niraparib studies in ovarian cancer.

Amod A. Sarnaik

Surgical Oncologist, Cutaneous Oncology; Senior Member · Moffitt Cancer Center

Amod Sarnaik led the pivotal lifileucel trial that produced the first approved TIL therapy.

Ana Oaknin

Head of the Gynaecological Cancer Programme, Vall d'Hebron Institute of Oncology, Barcelona · Vall d'Hebron University Hospital / VHIO

Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers.

Ananya Choudhury

Professor of Clinical Oncology, University of Manchester; Consultant, The Christie · The Christie NHS Foundation Trust

Ananya Choudhury is a clinical oncologist developing biomarker-guided radiotherapy for bladder cancer.

Ander Urruticoechea

Presidente (President) of GEICAM, the Spanish Breast Cancer Group · GEICAM Spanish Breast Cancer Group

Medical oncologist from Gipuzkoa who became President of GEICAM, Spain's academic breast cancer research group, in 2025 on the retirement of its founder Miguel Martín.

André Ilbawi

Technical Lead for Cancer Control, World Health Organization

The WHO's lead on cancer control, steering the cervical cancer elimination and global breast and childhood cancer initiatives.

Andrea Agnelli

Representative of Istituto di Candiolo IRCCS (FPO) to the Organisation of European Cancer Institutes · Istituto di Candiolo IRCCS (FPO)

Andrea Agnelli represents Istituto di Candiolo IRCCS (FPO) in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.

Andrea Cercek

Section Head, Colorectal Cancer; Co-Director, Center for Young Onset Colorectal and GI Cancers · Memorial Sloan Kettering Cancer Center

Led the study in which every patient with mismatch-repair-deficient rectal cancer had a complete response to dostarlimab, without surgery or radiation.